Consistently, antitumor immunity to experimental syngeneic IDH1-mut gliomas induced by an IDH1-specific vaccine or checkpoint inhibition was significantly improved by inhibition of the enzymatic function of mutant IDH1 [59]. Here, IDH1 is linked to glioma.